Therapeutic Asset Ratings

gi-108

hb0028

hb0036

hec169096

human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker ²⁰⁹GSGGGGSGGGGSGGGGS²²⁵ to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins²²⁶>A, S²³⁶>P (226-238), CH2 F²⁴²>A, L²⁴³>A, T²⁵⁸>Q (239-348), CH3 M⁴³⁶>L (349-453), CHS K⁴⁵⁵>del (454)] fused via peptide/ linker ⁴⁵⁵GGGGS⁴⁵⁹ to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R³⁸>A⁴⁹⁷, F⁴²>A⁵⁰¹), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

hy05350 for

(-)-Hydroxyurea methylacylfulvene

Idp-001

Ifinatamab Deruxtecan

IMM-1-104

Immunoglobulin G1 [241-aspartic acid,334-glutamic acid], anti-(human/Mus musculus/Macaca/Rattus claudin CLDN18.2) (human-Mus musculus monoclonal LM-102 ?1-chain), disulfide with human-Mus musculus monoclonal LM-102 ?-chain, dimer

imp1734

imp9064

Imx-110

ipg7236

ipn01195

ipn01203

Jab-23E73

js015

js207

Jskn033

kl590586

Ksq-001Ex

lat010

lb101